Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | NSD2 | O96028 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | BRD4 | O60885 | 1/20 | 0.30 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.30 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.30 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19538835 | 0.77 | PDE3B (0.40) | ALDH1A1MAPTKDM4ENSD2POLB | |
| SCHEMBL23508730 | 0.74 | PTPN11 (0.37) | ALDH1A1MAPTKDM4ENSD2 | |
| SCHEMBL27191847 | 0.74 | MAPT (0.34) | ALDH1A1MAPTKDM4ENSD2POLB | |
| SCHEMBL24163247 | 0.74 | MAPT (0.37) | ALDH1A1MAPTKDM4ENSD2POLB | |
| SCHEMBL27228498 | 0.74 | MAPT (0.42) | ALDH1A1MAPTKDM4ENSD2POLB | |
| SCHEMBL22349126 | 0.73 | MAPT (0.37) | ALDH1A1MAPTKDM4ENSD2 | |
| SCHEMBL29303145 | 0.71 | MAPT (0.36) | ALDH1A1MAPTKDM4ENSD2POLB | |
| SCHEMBL25669319 | 0.71 | MTNR1A (0.33) | ALDH1A1MAPTKDM4ENSD2POLB | |
| SCHEMBL21986777 | 0.70 | MTNR1A (0.34) | ALDH1A1MAPTKDM4ENSD2POLB | |
| SCHEMBL24858186 | 0.70 | MET (0.35) | ALDH1A1MAPTKDM4ENSD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10745385-B2 | Covalent inhibitors of KRAS | ARAXES PHARMA LLC (US) | 2020-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10745385-B2 | Covalent inhibitors of KRAS | KRAS, NRAS, HRAS | ALDH1A1 1640/4885MAPT 3575/4885KDM4E 2066/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.